Where does PGI Drug Discovery LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), PGI Drug Discovery LLC ranks #17,995 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does PGI Drug Discovery LLC hold?

PGI Drug Discovery LLC holds 16 US utility patents granted between 2016 and 2024, spanning 4 technology areas.

What is PGI Drug Discovery LLC's Innovation Score?

PGI Drug Discovery LLC has an Innovation Score of 34.1 out of 100 (46th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does PGI Drug Discovery LLC focus on?

PGI Drug Discovery LLC's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 16 patents, ranking #1,230 of 6,058 assignees active in that subclass. Grants appear in 4 CPC subclasses total.

Is PGI Drug Discovery LLC's patent grant rate increasing or decreasing?

PGI Drug Discovery LLC's recent grant velocity is +29% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for PGI Drug Discovery LLC's patents?

PGI Drug Discovery LLC's patents average 35.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the PGI Drug Discovery LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

PGI Drug Discovery LLC

USPTO PatentsView assignee record - 16 granted patents across 4 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, PGI ranks #17,995 of 49,997 tracked US assignees by granted-patent volume, with 16 patents across 4 technology areas.

#17,995
of 49,997 US assignees by volume: 46th percentile
by Innovation Score (34.1/100): 35.3
avg claims per patent: +29%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R17995 · US Corporation #17,995 · 16 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-MICRO 16 grants
MID-PACK #17,995/49,997
PHOTO-FINISH Pact XPP
CPC-NARROW A61P · 4 areas
INNOV-THIN 34.1/100
CLAIMS-DENSE 35.3 claims/avg
TYPE-USCORP US Corporation
VEL-UP +29% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Pact XPP Technologies AG (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How PGI’s 34.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.8 pts (29%) Velocity 2.2 pts (6%) Breadth 7.1 pts (21%) Claim depth 15.0 pts (44%)

Qualcomm Incorporated · highest

85
PGI Drug Discovery · this assignee

34
3D Lighting… · lowest

7

What this shows PGI's Innovation Score is 34.1/100 (46th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for PGI?

Each dot is one of PGI’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). PGI’s own 35.3 claims/patent is ABOVE the 7.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

PGI vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where PGI's grants concentrate

PGI Drug Discovery LLC is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (4 grants) versus a trough of 1 in 2016. By volume, PGI sits between Pact XPP Technologies AG and Plant Growers Australia PTY. Ltd..

PGI's three-year grant acceleration

PGI Drug Discovery LLC shows 3 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Pact XPP

16
PAO Shen Enterpri…

16
Peacock Apparel G…

16
Perseus Proteomics

16
Pgytech

16
Pharma MAR

16
Pkware

16
Plant Growers Aus…

16
PGI Drug Discovery ◀

16

What this shows PGI holds 16 patents at rank #17,982, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near PGI

By rank, the assignees closest to #17,982 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in PGI's primary technology class.

PGI's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 46th percentile higher than 46% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

PGI Drug Discovery LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	6.3%
2017	1	6.3%
2018	2	12.5%
2019	3	18.8%
2020	2	12.5%
2021	4	25.0%
2022	2	12.5%
2024	1	6.3%

Which technologies does PGI Drug Discovery LLC patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 16

C07D - Heterocyclic Compounds 16

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

PGI Drug Discovery LLC's patent record in context - here's where to go next.

PGI Drug Discovery LLC's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #17,995 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare PGI Drug Discovery LLC against Pact XPP Technologies AG, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.